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BACKGROUND
ATP citrate lyase is an enzyme in the cholesterol–biosynthesis pathway upstream 
of 3-hydroxy-3-methylglutaryl–coenzyme A reductase (HMGCR), the target of statins. 
Whether the genetic inhibition of ATP citrate lyase is associated with deleterious 
outcomes and whether it has the same effect, per unit decrease in the low-density 
lipoprotein (LDL) cholesterol level, as the genetic inhibition of HMGCR is unclear.
METHODS
We constructed genetic scores composed of independently inherited variants in the 
genes encoding ATP citrate lyase (ACLY) and HMGCR to create instruments that 
mimic the effect of ATP citrate lyase inhibitors and HMGCR inhibitors (statins), 
respectively. We then compared the associations of these genetic scores with plasma 
lipid levels, lipoprotein levels, and the risk of cardiovascular events and cancer.
RESULTS
A total of 654,783 participants, including 105,429 participants who had major cardio-
vascular events, were included in the study. The ACLY and HMGCR scores were associ-
ated with similar patterns of changes in plasma lipid and lipoprotein levels and 
with similar effects on the risk of cardiovascular events per decrease of 10 mg per 
deciliter in the LDL cholesterol level: odds ratio for cardiovascular events, 0.823 
(95% confidence interval [CI], 0.78 to 0.87; P = 4.0×10−14) for the ACLY score and 
0.836 (95% CI, 0.81 to 0.87; P = 3.9×10−19) for the HMGCR score. Neither lifelong 
genetic inhibition of ATP citrate lyase nor lifelong genetic inhibition of HMGCR 
was associated with an increased risk of cancer.
CONCLUSIONS
Genetic variants that mimic the effect of ATP citrate lyase inhibitors and statins 
appeared to lower plasma LDL cholesterol levels by the same mechanism of action 
and were associated with similar effects on the risk of cardiovascular disease per 
unit decrease in the LDL cholesterol level. (Funded by Esperion Therapeutics and 
others.)
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ATP citrate lyase is an enzyme in the cholesterol–biosynthesis pathway located upstream of 3-hydroxy-3-methylglutaryl–
coenzyme A reductase (HMGCR).1 Inhibition of 
ATP citrate lyase should therefore reduce the 
plasma low-density lipoprotein (LDL) cholesterol 
level by interfering with the same pathway as in-
hibition of HMGCR with a statin; thus, ATP citrate 
lyase is an emerging target for pharmacotherapy. 
It is unclear whether lowering LDL cholesterol 
levels by inhibiting ATP citrate lyase will reduce 
the risk of cardiovascular events to the same ex-
tent as inhibiting HMGCR with a statin.
Bempedoic acid is an oral ATP citrate lyase 
inhibitor that has been shown in randomized tri-
als of approximately 12 weeks’ duration to reduce 
LDL cholesterol levels by up to 30% when used 
alone and by up to 50% in combination with 
ezetimibe.2-4 In the Cholesterol Lowering via Bem-
pedoic Acid, an ACL-Inhibiting Regimen (CLEAR) 
Harmony trial, the results of which are reported 
in this issue of the Journal,5 the difference between 
bempedoic acid and placebo at 12 weeks with re-
spect to the change from baseline in the LDL 
cholesterol level was 18.1 percentage points in 
patients who were already receiving high- or 
moderate-intensity statin therapy. Although the 
incidence of cardiovascular events in that trial 
was lower among patients who received bempe-
doic acid than among those who received placebo, 
there was also a greater number of deaths from 
cardiovascular disease and cancer among partici-
pants who received the intervention; this raises 
the question of whether the inhibition of ATP ci-
trate lyase by bempedoic acid or by another drug 
could be harmful. However, the trial was not de-
signed to detect significant differences in the in-
cidence of major adverse cardiac events or other 
outcomes.
We sought to estimate the clinical effect of 
lowering plasma LDL cholesterol levels through 
inhibition of ATP citrate lyase by comparing vari-
ants in ACLY that mimic the effect of an ATP ci-
trate lyase inhibitor with variants in HMGCR that 
mimic the effect of a statin. Because bempedoic 
acid is likely to be used in combination with 
statins or ezetimibe, we also evaluated the effect 
of ACLY variants in combination with variants in 
HMGCR and NPC1L1 (Niemann–Pick C1–like 1), 
which encode proteins targeted by statins and 
ezetimibe, respectively. This approach has been 
used to accurately anticipate the results of several 
randomized trials that have evaluated other lipid-
lowering therapies.6-9 The objective of our study 
was to provide a biologic context for interpreting 
the results of the completed trials of ATP citrate 
lyase inhibitors, inform the design of future trials 
of ATP citrate lyase inhibitors, and anticipate, at 
least partially, the expected clinical effect of in-
hibition of ATP citrate lyase.
Me thods
Study Population
The study included 470,478 participants with in-
dividual-level data, including 367,641 participants 
who were enrolled in the U.K. Biobank study and 
102,837 participants who were enrolled in one of 
the 14 prospective cohort or case–control studies 
as part of the Database of Genotypes and Pheno-
types program of the National Center for Bio-
technology Information. The study also included 
184,305 participants enrolled in one of the 48 
prospective cohort, case–control, or cross-sectional 
studies included the Coronary Artery Disease Ge-
nomewide Replication and Meta-Analysis plus the 
Coronary Artery Disease (CARDIoGRAMplusC4D) 
consortium and 159,208 participants enrolled in 
one of the 18 studies included in the Diabetes Ge-
netics Replication and Meta-Analysis (DIAGRAM) 
consortium for whom summary-level data were 
available.10-13 Written informed consent was ob-
tained from all the participants in each of the 
contributing studies. A description of the included 
studies and the genotyping platforms that were 
used in each study is provided in Table S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.
Genetic Instruments
We constructed the genetic score for ACLY by com-
bining all variants within ACLY (and also within 
500 kb on either side of it) that were associated 
with plasma LDL cholesterol levels at a level of 
significance of less than 0.05, conditional on all 
other variants included in the score, and that were 
in low linkage disequilibrium (r2<0.3).14,15 Of the 
two alternative ACLY variants (or alleles) at each 
locus, the exposure allele was defined as the allele 
associated with a lower plasma LDL cholesterol 
level.15,16 For each study participant, we calculated 
an ACLY genetic score by adding the number of LDL 
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cholesterol–lowering alleles that he or she had in-
herited at each variant that was included in the 
ACLY score, weighted by the conditional effect of 
each variant on plasma LDL cholesterol levels 
measured in milligrams per deciliter. For com-
parison, we also constructed genetic scores for 
HMGCR and NPC1L1, which encode proteins tar-
geted by statins and ezetimibe, respectively, as 
previously described.6-8
Study Outcomes
The primary efficacy outcome for the study was 
major cardiovascular events (defined as a compos-
ite of the first occurrence of myocardial infarction, 
coronary revascularization, ischemic stroke, or 
coronary death). The key secondary outcome was 
myocardial infarction. The primary safety outcome 
was any type of cancer, and the key secondary 
safety outcome was diabetes. Changes in plasma 
lipid levels, lipoprotein levels, and the lipoprotein 
particle concentration were used to compare the 
lipidomic signatures of the ACLY and HMGCR 
scores. A description of the data used in each 
analysis is provided in Table S2 in the Supplemen-
tary Appendix.
Study Design and Oversight
The primary analysis measured the association 
between the ACLY score and changes in plasma 
lipid levels, lipoprotein levels, and the risk of ma-
jor cardiovascular events. To assess for an effect 
modification between ATP citrate lyase inhibition 
and either HMGCR or NPC1L1 inhibition, we mea-
sured the association between the ACLY genetic 
score and plasma lipoprotein levels and the risk 
of major cardiovascular events stratified according 
to the HMGCR and NPC1L1 genetic scores, respec-
tively. To evaluate the combined effect of ATP 
citrate lyase inhibition with either HMGCR or 
NPC1L1 inhibition, we evaluated the combined 
association of the ACLY and HMGCR or NPC1L1 
scores with changes in plasma lipid levels, lipo-
protein levels, and the risk of major cardiovascular 
events using a two-by-two factorial mendelian 
randomization analysis.6-9 Although this study was 
funded by the manufacturer of bempedoic acid, 
the sponsor had no access to the data; had no role 
in the design, conduct, or analysis of the study; 
had no role in the drafting of the manuscript or 
its content; and did not participate in the deci-
sion to submit the manuscript for publication.
Statistical Analysis
We estimated the association of each genetic 
score with continuous outcomes, including plasma 
lipid and lipoprotein levels, using linear regression, 
and we estimated the association of each genetic 
score with the risk of major cardiovascular events 
and other dichotomous outcomes using logistic 
regression. All regression analyses were performed 
separately in each of the included studies with ad-
justment for age, sex, and the first five principal 
Variable
Participants 
(N = 654,783)
No. of participants with available data
Individual data 470,478
Summary data 184,305
No. of participants with major cardio-
vascular events
105,429
Age (yr) 62.8±8.0
Female sex (%) 51.4
Blood pressure (mm Hg)
Systolic 132.1±18.2
Diastolic 80.9±9.3
Body-mass index† 27.5±4.9
Diabetes (%) 4.6
Current smoker (%) 9.2
Lipid levels (mg/dl)
Total cholesterol 206.6±39.4
LDL cholesterol 129.7±32.1
HDL cholesterol 52.0±15.4
Non-HDL cholesterol 154.9±38.3
Apolipoprotein B 101.4±27.3
Triglyceride level (mg/dl)
Median 117.6
Interquartile range 84–163
*  Plus–minus values are means ±SD. Data on age and sex were available for all 
654,783 participants. Data on baseline characteristics other than plasma lipid 
and lipoprotein levels were available for participants who were enrolled in the 
U.K. Biobank cohort and the 14 case–control or cohort studies in the Database 
of Genotypes and Phenotypes program (dbGAP) for whom individual data were 
available. Data on plasma lipid and lipoprotein levels were available for partici-
pants who were enrolled in the dbGAP studies and who had one or more lipid 
measurements (lipid measurements for U.K. Biobank participants had not yet 
been released). To convert values for cholesterol to millimoles per liter, multiply 
by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 
0.01129. HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.
†  Body-mass index is the weight in kilograms divided by the square of the 
height in meters.
Table 1. Baseline Characteristics of the Participants.*
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components of ancestry for participants with indi-
vidual-level data, or with the ratio of effect es-
timates method for studies that provided sum-
mary-level data. These effect estimates were then 
combined across studies in a fixed-effects in-
verse-variance–weighted meta-analysis to produce 
summary estimates of effect with the use of a 
previously reported method that accounts for cor-
relation among variants included in a genetic 
score.17 To compare the association of the genetic 
scores with changes in plasma lipoprotein levels 
and the risk of cardiovascular events, we adjusted 
each effect-size estimate to scale the results for 
a standard decrement of 10 mg per deciliter 
(0.26 mmol per liter) in the LDL cholesterol level.
All analyses were performed with the use of 
Stata software, version 14 (StataCorp), R software, 
version 3.2.2 (R Foundation for Statistical Com-
puting), and SNP & Variation Suite software, ver-
sion 8.1.4 (Golden Helix). A detailed description 
of the methods, including a description of both 
mendelian randomization and factorial mendelian 
randomization, is provided in the Methods section 
in the Supplementary Appendix.
R esult s
Participant Characteristics
A total of 654,783 participants, including 105,429 
participants who had a major cardiovascular event, 
were included in the efficacy analysis. A total of 
656,895 participants, including 37,994 participants 
who had cancer and 53,145 participants who had 
diabetes, were included in the safety analysis. Indi-
vidual participant–level data were available for 
470,478 participants, including 44,628 participants 
who had a major cardiovascular event, 26,646 par-
ticipants who had cancer, and 26,469 participants 
who had diabetes (Table 1). The mean age among 
all 654,783 participants was 62.8 years, and 51.4% 
were women.
Genetic Scores
Nine independently inherited variants were in-
cluded in the ACLY score, six in the HMGCR score, 
and five in the NPC1L1 score (Tables S3 through 
S8 in the Supplementary Appendix). Although each 
variant included in the ACLY score was only weakly 
conditionally associated with plasma LDL choles-
terol levels, the ATP citrate lyase score was ro-
bustly associated with LDL cholesterol levels. A 
1-unit increase in the ACLY score was associated 
with an inverse-variance–weighted mean decrease 
of 1.21 mg per deciliter (95% confidence interval 
[CI], 0.94 to 1.48; P = 1.6×10−18) (0.03 mmol per 
liter; 95% CI, 0.02 to 0.04) in the plasma LDL 
cholesterol level and a concordant decrease of 
1.00 mg per deciliter (95% CI, 0.77 to 1.23; 
P = 7.2×10−17) in the plasma apolipoprotein B level. 
In additional analyses involving 65,976 partici-
pants with lipid traits measured with the use of 
nuclear magnetic resonance spectroscopy, the 
ACLY and HMGCR scores were associated with a 
similar pattern of changes in the concentration 
and lipid composition of plasma lipoproteins; this 
suggests that they lower plasma LDL cholesterol 
levels by affecting the same metabolic pathway 
(Fig. 1).
Association of Genetic Scores  
with Cardiovascular Events
For each decrease of 10 mg per deciliter in the LDL 
cholesterol level, the ACLY score was associated 
with a decrease of 17.7% in the risk of major car-
diovascular events (odds ratio, 0.823; 95% CI, 0.78 
to 0.87; P = 4.0×10−14) and a 19.4% decrease in the 
risk of myocardial infarction (odds ratio, 0.806; 
95% CI, 0.76 to 0.86; P = 6.4×10−12). The association 
of the ACLY score was similar to the association 
of the HMGCR score with the risk of major cardio-
vascular events (odds ratio, 0.836; 95% CI, 0.81 
to 0.87; P = 3.9×10−19) and the risk of myocardial 
infarction (odds ratio, 0.827; 95% CI, 0.79 to 0.87; 
P = 2.6×10−14) for each decrease of 10 mg per deci-
liter in the LDL cholesterol level.
Figure 1 (facing page). Associations of the ACLY and 
HMGCR Scores with Changes in the Concentration 
and Lipid Composition of Plasma Lipoproteins.
HMGCR (3-hydroxy-3-methylglutaryl–coenzyme A re-
ductase) scores are shown in blue, and ACLY (ATP ci-
trate lyase) scores are shown in red. Data are from 
analyses involving 65,976 participants for whom lipid 
traits measured with the use of nuclear magnetic reso-
nance spectroscopy were available. The change for 
each lipid trait is expressed as a percentage of the 
change in the low-density lipoprotein (LDL) cholester-
ol level, with both measurements in SD units. Boxes 
represent point estimates of effect, and lines 95% 
confidence intervals. HDL denotes high-density lipo-
protein, IDL intermediate-density lipoprotein, and 
VLDL very-low-density lipoprotein.
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In addition, the ACLY and HMGCR genetic scores 
had similar associations with multiple different 
composite cardiovascular outcomes as well as with 
the individual components of those composite 
outcomes, including death from coronary heart 
disease (Fig. 2A, and Table S9 in the Supplemen-
tary Appendix). Furthermore, the association of 
the ACLY score was also similar to the association 
of the scores for NPC1L1, proprotein convertase 
subtilisin–kexin type 9 (PCSK9), and the gene en-
coding the LDL receptor (LDLR) with the risk of 
major cardiovascular events for each decrease of 
10 mg per deciliter in the LDL cholesterol level 
(Fig. 2B).
Associations of Combined Genetic Scores 
with Lipids and Major Cardiovascular Events
The associations of the ACLY score with plasma 
apolipoprotein B levels and the risk of major car-
diovascular events did not change in analyses 
stratified according to the HMGCR and NPC1L1 
scores, respectively (Fig. 3A). Furthermore, in two-
by-two factorial mendelian randomization analy-
ses, combined exposure to both the ACLY and 
HMGCR scores, as well as combined exposure to the 
ACLY and NPC1L1 scores, was associated with inde-
pendent and linearly additive decreases in plasma 
LDL cholesterol and apolipoprotein B levels and 
corresponding independent and log-additive de-
Figure 2. Associations of the Genetic Scores with the Risk of Cardiovascular Events.
Panel A shows the association between the ACLY score and the risk of cardiovascular events per decrease of 10 mg 
per deciliter in the LDL cholesterol level, and Panel B shows the comparison of the association of the ACLY score 
and that of the other genetic scores with the risk of major cardiovascular events for the same decrease of 10 mg per 
deciliter in the LDL cholesterol level. Data on major cardiovascular events and myocardial infarctions are from anal-
yses involving the total study sample of 654,783 participants; these analyses included both individual participant–
level and summary-level data. Data on major coronary events, coronary heart disease, coronary revascularization, 
and death from coronary heart disease are from the sample of 470,478 participants for whom individual-level data 
on these outcomes were available. Associations for all genetic scores are given for a standardized decrement of 10 mg 
per deciliter in the LDL cholesterol level. Boxes represent point estimates of effect, and lines 95% confidence inter-
vals. Major coronary events were defined as the composite of nonfatal myocardial infarction, coronary revasculariza-
tion, or death from coronary heart disease. Coronary heart disease was defined as the composite of nonfatal myo-
cardial infarction or death from coronary heart disease, and coronary revascularization was defined as percutaneous 
coronary intervention or coronary-artery bypass grafting surgery. LDLR denotes LDL receptor, NPC1L1 Niemann–
Pick C1–like 1, and PCSK9 proprotein convertase subtilisin–kexin type 9.
B All Scores
A ACLY Score
1.00.9
Proportional Effect Relative to Effect on LDL Cholesterol Level
Primary outcome
Major cardiovascular event
Secondary outcomes
Major coronary event
Coronary heart disease
Myocardial infarction
Coronary revascularization
Death from coronary heart disease
1.21.10.8
Outcome No. of Participants
Odds Ratio for Cardiovascular Events per Decrease
of 10 mg/dl in LDL Cholesterol Level (95% CI)
105,429
28,591
23,995
65,145
11,426
4,348
0.7
0.82 (0.78–0.87)
0.83 (0.78–0.89)
0.83 (0.76–0.90)
0.81 (0.76–0.86)
0.82 (0.75–0.91)
0.86 (0.74–1.00)
1.00.9
Proportional Effect Relative to Effect on LDL Cholesterol Level
ACLY
HMGCR
NPC1L1
PCSK9
LDLR
1.21.10.8
Genetic Score
Odds Ratio for Cardiovascular Events per Decrease
of 10 mg/dl in LDL Cholesterol Level (95% CI)
0.7
0.82 (0.78–0.87)
0.84 (0.82–0.87)
0.84 (0.79–0.89)
0.83 (0.80–0.87)
0.82 (0.80–0.85)
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creased risks of major cardiovascular events 
(Fig. 3B and 3C).
Associations of ACLY and HMGCR Scores  
with Cancer and Other Adverse Outcomes
Neither the ACLY score nor the HMGCR score was 
associated with an increased risk of all cancers 
combined or any site-specific cancer (Table 2). 
Although there was weak evidence that the ACLY 
score may have been associated with a decreased 
risk of lung cancer, this finding should be in-
terpreted with caution because the associations 
between lung cancer and the ACLY score and 
between lung cancer and the HMGCR score did 
not differ significantly (Table 2). In contrast, 
the HMGCR, NPC1L1, PCSK9, and LDLR scores 
were associated with an increased risk of dia-
betes, but the ACLY score was not (Table 2, and 
Tables S10 through S12 in the Supplementary 
Appendix).
Figure 3. Associations of the ACLY Score, Alone and in Combination with the HMGCR and NPC1L1 Scores,  
with Lipoprotein Levels and the Risk of Major Cardiovascular Events.
Panel A shows the stratified analysis. Panel B shows a two-by-two (2×2) factorial mendelian randomization analysis 
of ACLY and HMGCR scores. Panel C shows a two-by-two factorial mendelian randomization analysis of ACLY and 
NPC1L1 scores. Data are from analyses involving 470,478 participants for whom individual participant data, includ-
ing 44,628 cases of major cardiovascular events, were available. Changes in lipid levels were obtained from 72,411 
participants with individual participant data who were enrolled in the Database of Genotypes and Phenotypes  
(dbGAP) or the U.K. National Health Service Blood and Transplant INTERVAL study18 and for whom one or more 
lipid measurements were available. The solid boxes represent point estimates of effect, and lines 95% confidence 
intervals.
B Combined Effect of ACLY and HMGCR Scores
A Effect of ACLY Score, Stratified According to HMGCR and NPC1L1 Scores
1.00.9
HMGCR score
≤Median
>Median
NPC1L1 score
≤Median
>Median
1.21.10.8
Genetic Score
No. of
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Odds Ratio for Major Cardiovascular
Events per Decrease of 10 mg/dl
in LDL Cholesterol Level
(95% CI)
245,402
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237,024
233,454
Change in Apolipoprotein B
  Level per Decrease of 10 mg/dl
in LDL Cholesterol Level
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−7.8 (–11.4 to –4.2)
−8.0 (–11.6 to –4.3)
−8.4 (–12.1 to –4.6)
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0.83 (0.77 to 0.91)
0.85 (0.78 to 0.92)
0.83 (0.77 to 0.91)
0.84 (0.78 to 0.92)
1.00.9
Both scores >median
HMGCR score >median
ACLY score >median
Both scores ≤median
1.21.10.8
2×2 Analysis
No. of
Participants
Odds Ratio for Major Cardiovascular Events 
(95% CI)
101,623
124,206
110,092
134,557
Change in
Apolipoprotein B
Level (95% CI)
−4.2 (–3.8 to –1.5)
−2.7 (–3.8 to –1.5)
−2.0 (–3.3 to –0.7)
Reference
Change in LDL
Cholesterol Level
(95% CI)
−5.3 (–6.6 to –3.9)
−3.3 (–4.6 to –2.0)
−2.4 (–3.9 to –0.8)
Reference
0.7
0.91 (0.88 to 0.94)
0.94 (0.91 to 0.98)
0.96 (0.93 to 0.99)
Reference
C Combined Effect of ACLY and NPC1L1 Scores
1.00.9
Both scores >median
NPC1L1 score >median
ACLY score >median
Both scores ≤median
1.21.10.8
2×2 Analysis
No. of
Participants
Odds Ratio for Major Cardiovascular Events
(95% CI)
105,011
128,346
106,705
130,416
Change in
Apolipoprotein B
Level (95% CI)
−4.1 (–5.4 to –2.7)
−1.9 (–3.3 to –0.5)
−2.0 (–3.4 to –0.7)
Reference
Change in LDL
Cholesterol Level
(95% CI)
−5.2 (–7.2 to –3.2)
−2.5 (–4.2 to –0.8)
−2.5 (–4.0 to –0.9)
Reference
0.7
0.90 (0.87 to 0.93)
0.96 (0.92 to 0.99)
0.95 (0.92 to 0.99)
Reference
mg/dl per 10 mg/dl
mg/dl
mg/dl
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Discussion
We found that variants in ACLY and HMGCR were 
associated with similar patterns of changes in 
the concentration and lipid composition of plasma 
lipoproteins and had a nearly identical effect on 
the risk of cardiovascular events for each unit de-
crease in the LDL cholesterol level. The results of 
our study thus confirm the mechanism by which 
ATP citrate lyase inhibition lowers plasma LDL 
cholesterol levels, and they provide validation for 
ATP citrate lyase inhibition as a genetic target.
We also found that the lipidomic signature of 
LDL cholesterol–lowering ACLY variants was sim-
ilar to that of LDL cholesterol–lowering HMGCR 
variants, which in turn are associated with a simi-
Variable ACLY Variants HMGCR Variants
P Value 
for Difference
No. of Cases
Odds Ratio 
(95% CI)† P Value
Odds Ratio 
(95% CI)† P Value
Cancer
Any cancer 26,576 1.00 
(0.99 to 1.01)
0.13 1.00 
(0.99 to 1.01)
0.11 0.17
Lung cancer
Any lung cancer 11,348 0.77 
(0.64 to 0.93)
0.01 1.05 
(0.96 to 1.16)
0.26 0.24
Adenocarcinoma of the lung 3,442 0.79 
(0.59 to 2.06)
0.12 1.10 
(0.95 to 1.26)
0.21 0.19
Squamous-cell lung cancer 3,275 0.71 
(0.53 to 0.95)
0.02 1.04 
(0.90 to 1.20)
0.58 0.27
Breast cancer 7,480 1.00 
(0.99 to 1.01)
0.91 1.00 
(0.99 to 1.01)
0.49 0.49
Prostate cancer 2,495 1.00 
(0.99 to 1.01)
0.29 1.00 
(0.99 to 1.01)
0.47 0.32
Lung cancer in father 27,424 1.00 
(0.99 to 1.01)
0.66 1.00 
(0.99 to 1.01)
0.45 0.23
Breast cancer in mother 25,865 1.00 
(0.99 to 1.01)
0.87 1.00 
(0.99 to 1.01)
0.58 0.58
Conditions other than cancer
Change in blood pressure
Systolic 470,478 −0.18 
(−0.49 to 0.13)
0.24 0.05 
(−0.18 to 0.29)
0.62 0.23
Diastolic 470,478 −0.02 
(−0.18 to 0.14)
0.81 −0.08 
(−0.19 to 0.04)
0.19 0.52
Hypertension 118,064 0.99 
(0.98 to 1.01)
0.09 1.00 
(0.99 to 1.01)
0.94 0.21
Diabetes 53,145 0.97 
(0.93 to 1.00)
0.05 1.08 
(1.05 to 1.12)
3.32×10−6 3.03×10−6
Gout 4,807 1.00 
(0.99 to 1.01)
0.90 1.00 
(0.99 to 1.01)
0.21 0.43
*  Effect sizes are presented as associations between either genetic score and the various outcomes standardized for a decrease of 10 mg per 
deciliter in the LDL cholesterol level. Analyses of cancer outcomes included 367,641 participants with individual-level data who were enrolled in 
the U.K. Biobank study. The analysis of lung cancer was supplemented with summary data from 27,209 participants (including 11,348 par-
ticipants with lung cancer) who were enrolled in the International Lung Cancer Consortium.19 Analyses of noncancer outcomes included 
367,641 participants with individual-level data who were enrolled in the U.K. Biobank study. The analysis of diabetes risk is from a combined 
analysis involving 629,686 participants, including 470,478 participants with individual-level data from the U.K. Biobank and dbGAP studies and 
159,208 participants with summary data from the DIAGRAM (Diabetes Genetics Replication and Meta-Analysis) consortium studies.13
†  The data shown are odds ratios, with the exception of change in blood pressure, which is an effect size.
Table 2. Associations of the ACLY and HMGCR Genetic Scores with Cancer and Other Conditions.*
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lar lipidomic signature as treatment with a statin.20 
This finding strongly implies that inhibiting ATP 
citrate lyase reduces plasma LDL cholesterol lev-
els in the same way that inhibiting HMGCR with 
a statin reduces LDL cholesterol levels — that is, 
by reducing the concentration of LDL particles 
through up-regulation of the LDL receptor. There-
fore, our study provides genetic validation for 
the proposed mechanism of action by which ATP 
citrate lyase inhibition reduces plasma LDL cho-
lesterol levels.1
In addition, our finding that ACLY variants 
associated with decreased LDL cholesterol levels 
are also associated with a decreased risk of cardio-
vascular events provides genetic validation for ATP 
citrate lyase as a therapeutic target. More relevant 
clinically, we found that genetic variants that 
mimic the effect of ATP citrate lyase inhibitors, 
statins, and ezetimibe, both alone and in com-
bination, were all associated with similar effects 
on the risk of cardiovascular events per unit de-
crease in the LDL cholesterol level. Because long-
term exposure to decreased LDL cholesterol levels 
associated with genetic variants that mimic the 
action of ATP citrate lyase inhibitors and statins 
has the same effect on the risk of cardiovascular 
events per unit decrease in the LDL cholesterol 
level, it is reasonable to assume that shorter-term 
pharmacologic reductions in LDL cholesterol levels 
due to treatment with an ATP citrate lyase inhibitor 
could have the same effect on the risk of cardio-
vascular events as treatment with a statin per unit 
decrease in the LDL cholesterol level. Therefore, 
we speculate that treatment with an ATP citrate 
lyase inhibitor, whether used alone or in combi-
nation with a statin or ezetimibe, would be likely 
reduce the risk of cardiovascular events by ap-
proximately 20% for each decrease of 39 mg per 
deciliter (1.0 mmol per liter) in the LDL cholesterol 
level.21 This speculation assumes that an ATP ci-
trate lyase inhibitor has no off-target effects; this 
is impossible to determine without large and long 
clinical trials.
Furthermore, we found that decreased LDL 
cholesterol levels associated with variants that 
mimic ATP citrate lyase inhibitors and statins had 
similar effects on multiple different cardiovascu-
lar events, including death from cardiovascular 
disease. Because randomized trials have shown 
that reducing LDL cholesterol levels with a statin 
reduces the risk of death from cardiovascular 
disease,21 it is reasonable to assume that lowering 
LDL cholesterol levels with an ATP citrate lyase 
inhibitor could also reduce the risk of death from 
cardiovascular disease. Again, this assumption is 
based on the unknown side effects and off-tar-
get effects of such an inhibitor. In addition, be-
cause genetic variants that mimic the effect of 
ATP citrate lyase inhibitors appear to lower LDL 
cholesterol levels by the same mechanism of ac-
tion as statins and because randomized trials have 
shown that treatment with a statin is not associ-
ated with an increased risk of cancer or death 
from cancer, it would seem reasonable to extrapo-
late that lowering LDL cholesterol levels with an 
ATP citrate lyase inhibitor would be unlikely to 
increase the risk of cancer.22 In the specific case 
of bempedoic acid, we cannot rule out the pos-
sibility that a drug-specific effect of this agent, 
unrelated to its intended mechanism of action, 
increases the risk of death from cancer.
Our study has limitations. First, as mentioned, 
genetic variants that mimic the effect of a thera-
peutic agent cannot anticipate potential drug-
specific adverse effects of a therapy that is not 
related to its mechanism of action (i.e., off-target 
effects). Second, genetic variants reflect the effect 
of lifelong exposure to a biomarker on an out-
come and therefore cannot be used to estimate 
the expected effect of short-term pharmacologic 
changes in that biomarker directly.9,23,24 Third, 
most major adverse effects tend to be uncom-
mon, leading to imprecise estimates of effect, 
particularly with genetic variants that have small 
effects on the exposure of interest. As a result, 
evaluation of the association between a genetic 
variant that mimics the effect of a therapeutic 
agent and numerous potential adverse outcomes 
can lead to both spurious suggestions of in-
creased risk and false reassurances of safety 
owing to potential off-target effects, imprecise 
estimates of effect, the play of chance related to 
multiple testing, and difficulties in translating 
the observed effect of lifelong exposure into the 
expected effect of short-term pharmacologic 
changes.
In conclusion, we found that genetic variants 
that mimic the effect of ATP citrate lyase inhibi-
tors and statins appeared to lower plasma LDL 
cholesterol levels by the same mechanism of ac-
tion. They were associated with nearly identical 
effects on the risk of cardiovascular disease and 
cancer per unit decrease in the LDL cholesterol 
level.
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